{"id":"rabies-vaccines-rabies-immunoglobulins","safety":{"commonSideEffects":[{"rate":"30-74","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"5-20","effect":"Headache"},{"rate":"5-15","effect":"Myalgia"},{"rate":"1-10","effect":"Fever"},{"rate":"1-5","effect":"Nausea"},{"rate":"<1","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1201600","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabies vaccines contain inactivated or attenuated rabies virus antigens that trigger active humoral and cellular immune responses, generating long-lasting antibodies and memory cells. Rabies immunoglobulins (RIG) provide rapid passive immunity by delivering pre-formed anti-rabies antibodies that neutralize virus before active immunity develops, critical in post-exposure prophylaxis where the incubation period is short.","oneSentence":"Rabies vaccines stimulate immune response against rabies virus, while rabies immunoglobulins provide immediate passive immunity through pre-formed antibodies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:09.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of rabies virus infection"},{"name":"Pre-exposure prophylaxis in high-risk populations"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT07399951","phase":"EARLY_PHASE1","title":"Washington University WU 409: Immune Responses to Rabies Vaccine.","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-07-18","conditions":"Healthy Participants","enrollment":30},{"nctId":"NCT03961555","phase":"PHASE2","title":"Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2019-09-03","conditions":"Rabies","enrollment":448},{"nctId":"NCT07342257","phase":"PHASE1","title":"SYN023 With Rabies Vaccine in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2024-11-30","conditions":"Rabies Post-exposure Prophylaxis","enrollment":108},{"nctId":"NCT07168018","phase":"PHASE2","title":"Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12","conditions":"Rabies","enrollment":40},{"nctId":"NCT04270838","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2022-02-17","conditions":"Rabies","enrollment":174},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT04594551","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-11","conditions":"Rabies (Healthy Volunteers)","enrollment":201},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT05846568","phase":"PHASE3","title":"Study to Evaluate GR1801's Efficacy and Safety","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-10-21","conditions":"Rabies Post-exposure Prophylaxis","enrollment":1200},{"nctId":"NCT06548139","phase":"PHASE2","title":"Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-07-31","conditions":"Rabies Virus Infection","enrollment":120},{"nctId":"NCT02545517","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Virus Diseases, Rabies","enrollment":459},{"nctId":"NCT05135273","phase":"PHASE1","title":"Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-22","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT06177249","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2015-03-15","conditions":"Rabies Human","enrollment":1956},{"nctId":"NCT05832073","phase":"EARLY_PHASE1","title":"Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-04-30","conditions":"Rabies Virus Infection","enrollment":152},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":"Rabies, Communicable Disease, Virus Diseases","enrollment":1000},{"nctId":"NCT05547815","phase":"PHASE4","title":"Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine","status":"COMPLETED","sponsor":"Changchun Zhuoyi Biological Co., Ltd","startDate":"2019-11-11","conditions":"Rabies, Antibody","enrollment":149},{"nctId":"NCT02547727","phase":"NA","title":"Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2016-02","conditions":"Rabies","enrollment":40},{"nctId":"NCT03524417","phase":"NA","title":"Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2018-04-30","conditions":"Rabies","enrollment":20},{"nctId":"NCT03729102","phase":"NA","title":"Immunological Tolerance After Frequent Rabies Booster Vaccinations","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2020-06-04","conditions":"Rabies","enrollment":60},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320},{"nctId":"NCT00000904","phase":"PHASE1","title":"Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00023504","phase":"PHASE4","title":"Antibody Production in Immune Disorders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-06-13","conditions":"Primary Immune Deficiency","enrollment":21},{"nctId":"NCT02040090","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2013-04","conditions":"Rabies","enrollment":118},{"nctId":"NCT04495569","phase":"PHASE1, PHASE2","title":"A Bridging Study of the SYN023 on Healthy Adult Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2019-02-26","conditions":"Communicable Disease Transmission, Zoonotic Disease, Rabies Human","enrollment":33},{"nctId":"NCT04213950","phase":"NA","title":"Improving Adherence to Rabies PEP Guideline Recommendations","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-12-29","conditions":"Rabies, Rabies Human, Rabies Virus Infection","enrollment":70},{"nctId":"NCT03264157","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Bio Products Laboratory","startDate":"2017-12-08","conditions":"Healthy","enrollment":162},{"nctId":"NCT02956746","phase":"PHASE1, PHASE2","title":"A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2016-08","conditions":"Human Rabies","enrollment":164},{"nctId":"NCT01949909","phase":"PHASE1","title":"Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2014-03","conditions":"Malaria","enrollment":56},{"nctId":"NCT01610362","phase":"NA","title":"Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2012-06","conditions":"Rabies","enrollment":50},{"nctId":"NCT01641315","phase":"NA","title":"Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2015-09","conditions":"Rabies","enrollment":75},{"nctId":"NCT01137045","phase":"PHASE4","title":"Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2010-06","conditions":"Rabies","enrollment":210},{"nctId":"NCT03192371","phase":"PHASE4","title":"A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-02-15","conditions":"Virus Diseases","enrollment":""},{"nctId":"NCT02991872","phase":"PHASE4","title":"A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-16","conditions":"Virus Diseases","enrollment":150},{"nctId":"NCT02177032","phase":"PHASE3","title":"Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-06","conditions":"Rabies Infection","enrollment":885},{"nctId":"NCT03093545","phase":"NA","title":"Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-03","conditions":"Rabies","enrollment":60},{"nctId":"NCT02559921","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2014-12","conditions":"Rabies","enrollment":300},{"nctId":"NCT01286493","phase":"NA","title":"Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2011-02","conditions":"HIV, Rabies","enrollment":33},{"nctId":"NCT01063140","phase":"","title":"Rabies Immune Plasma Booster Study","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2009-01","conditions":"Rabies","enrollment":491},{"nctId":"NCT02339896","phase":"","title":"Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2014-02","conditions":"Dog Bite","enrollment":45},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240},{"nctId":"NCT00708084","phase":"PHASE2","title":"Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2008-05","conditions":"Rabies","enrollment":48},{"nctId":"NCT01173302","phase":"PHASE4","title":"Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2010-05","conditions":"Rabies","enrollment":160},{"nctId":"NCT00703521","phase":"PHASE2","title":"Rabies Immunization Concomitant With JEV in Children","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2002-08","conditions":"Rabies","enrollment":200},{"nctId":"NCT00694460","phase":"PHASE2","title":"Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-08","conditions":"Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rabies vaccines + Rabies immunoglobulins","genericName":"Rabies vaccines + Rabies immunoglobulins","companyName":"Novartis","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"Rabies vaccines stimulate immune response against rabies virus, while rabies immunoglobulins provide immediate passive immunity through pre-formed antibodies. Used for Post-exposure prophylaxis of rabies virus infection, Pre-exposure prophylaxis in high-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}